Verastem Oncology says RAMP 201 analysis shows 18% ORR for avutometinib-defactinib in triple wild-type recurrent LGSOC

• Verastem Oncology outlined new analyses from its Phase 2 RAMP 201 study of avutometinib with defactinib in recurrent LGSOC.
• Results will be presented at the IGCS 2026 meeting in Montréal on Oct. 2, 2026.
• Molecular profiling showed the regimen produced meaningful responses in KRAS wild-type disease, including tumors lacking KRAS, NRAS, BRAF mutations.
• An external control analysis indicated better tumor response and longer disease control versus conventional chemotherapy or anti-estrogen care.
• Data reinforced the regimen’s role in KRAS-mutated first-recurrence LGSOC, supporting expansion efforts in KRAS wild-type patients.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Verastem Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20261002351312) on October 02, 2026, and is solely responsible for the information contained therein.